



Cytokinetics to Present Clinical Data on CK-1827452, a Selective Cardiac Myosin Activator, at the 2008 Heart Failure Congress of the European Society of Cardiology

June 9, 2008 8:01 PM EDT

Interim Phase IIa Clinical Trial Results to Be Presented at a Late Breaking Trials Session on June 16th; Investor Lunch and Webcast Scheduled

SOUTH SAN FRANCISCO, CA, Jun 09, 2008 (MARKET WIRE via COMTEX News Network) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that interim results from an ongoing Phase IIa clinical trial in stable heart failure patients evaluating CK-1827452, a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure, are scheduled to be presented as part of the Late Breaking Trials Session at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology, to be held June 14-17, 2008 in Milan, Italy.

Late Breaking Trials Presentation at Heart Failure Congress

Late Breaking Trials: "The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in Heart Failure" (Oral Presentation 564a on Monday, June 16, 2008, during the Late Breaking Trials session, 11:00 a.m. - 12:30 p.m. Milan Time; the presentation is scheduled to begin at 12:18 p.m. in the Auditorium of the Milano Convention Center). The presentation will be made by John Cleland, MD, FACC, FRCP, FESC, Professor of Cardiology, Castle Hill Hospital, University of Hull, United Kingdom.

Cytokinetics Investor Lunch and Webcast

Cytokinetics plans to host an Investor Lunch entitled "Interim Results of a Phase IIa Clinical Trial of CK-1827452 in Stable Heart Failure Patients" on Monday, June 16th from 1:00 p.m. - 2:00 p.m. Milan Time/ 7:00 a.m. - 8:00 a.m. Eastern Time. The event will be held in the White 1 Room on Level 2 at the Milano Convention Center, Milan, Italy. At this meeting, Robert Blum, Cytokinetics' President and Chief Executive Officer, will join Andrew Wolff, MD, FACC, Senior Vice President of Clinical Research and Development and Chief Medical Officer of Cytokinetics, and Dr. Cleland as well as John J.V. McMurray, MD, FACC, FRCP, FESC, Professor of Medical Cardiology at the University of Glasgow in Glasgow, Scotland, United Kingdom in a panel discussion. Mr. Blum will moderate the session. Dr. Wolff will review the Phase IIa clinical trial design. Dr. Cleland will review the interim results from this trial and Dr. McMurray will offer additional perspective on the clinical relevance of these data and the potential of CK-1827452 in the treatment of heart failure patients.

The presentation and accompanying slides will be simultaneously webcast beginning at 7:00 a.m. Eastern Time and can be accessed through the Investor Relations section of the Cytokinetics' website at www.cytokinetics.com. The live audio of the forum will also be accessible via telephone to investors, members of the news media and the general public by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 50722133.

An archived replay of the webcast will be available on the Presentations page in the Investor Relations section of Cytokinetics' website until July 18, 2008. The replay will also be available via telephone from June 16, 2008 at 10:00 a.m. Eastern Time until July 18, 2008 by dialing (800) 642-1687 (United States and Canada) or (706) 645-9291 (International) and typing in the passcode 50722133.

About Cytokinetics

Cytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that may address areas of significant unmet clinical needs. Cytokinetics' development activities are primarily directed to advancing multiple drug candidates through clinical trials with the objective of determining the intended pharmacodynamic effect or effects in two principal diseases: heart failure and cancer. Cytokinetics' cardiovascular disease program is focused to cardiac myosin, a motor protein essential to cardiac muscle contraction. Cytokinetics' lead compound from this program, CK-1827452, a novel small molecule cardiac myosin activator, entered Phase II clinical trials for the treatment of heart failure in 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen Inc. are performing joint research focused on identifying and characterizing activators of cardiac myosin as back-up and follow-on potential drug candidates to CK-1827452. Amgen has obtained an option for an exclusive license to develop and commercialize CK-1827452, subject to Cytokinetics' development and commercial participation rights. Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused on the potential treatment of cancer. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics believes clinical activity for ispinesib has been observed in Phase II monotherapy clinical trials in breast cancer, ovarian cancer and non-small cell lung cancer and recently initiated an additional Phase I/II clinical trial of ispinesib as monotherapy as a first-line treatment in chemotherapy-naïve patients with locally advanced or metastatic breast cancer on a more dose-dense schedule than previously studied. Cytokinetics is also conducting a Phase I/II trial of SB-743921 on a similar more dose-dense schedule in non-Hodgkin and Hodgkin lymphomas. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK, subject to Cytokinetics' option to co-fund certain later-stage development activities and to co-promote any resulting approved drug in North America. GSK began a Phase I clinical trial with GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of a potential drug candidate directed towards skeletal muscle contractility which may be developed as a potential treatment for skeletal muscle weakness associated with neuromuscular diseases or other conditions. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer and cardiovascular and other diseases. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development programs, including planned presentations relating to such research and development programs and clinical trial results; the potential benefits of CK-1827452 and Cytokinetics' other drug candidates and potential drug candidates; and the enabling capabilities of Cytokinetics' cytoskeletal focus. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval or production of CK-1827452 or Cytokinetics' other drug candidates that could slow or prevent clinical development, product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; GSK may decide to postpone or discontinue development activities for GSK-923295, Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products, standards of care may change, others may introduce products or alternative therapies for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target, and risks and uncertainties relating to the timing and receipt of payments from our partners, including milestones and royalties on future potential product sales under Cytokinetics' collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Contacts: [

Scott R. Jordan (Media)
Director, Corporate Development
(650) 624-3000

Christopher S. Keenan (Investors)
Director, Investor Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.